<?xml version="1.0" encoding="UTF-8"?>
<TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns="ted/R2.0.9.S02/publication"
            xmlns:n2016="ted/2016/nuts"
            xsi:schemaLocation="ted/R2.0.9.S02/publication TED_EXPORT.xsd"
            VERSION="R2.0.9.S02.E01"
            DOC_ID="043485-2018"
            EDITION="2018021">
   <TECHNICAL_SECTION>
      <RECEPTION_ID>18-043749-001</RECEPTION_ID>
      <DELETION_DATE>20180227</DELETION_DATE>
      <FORM_LG_LIST>EN </FORM_LG_LIST>
      <COMMENTS>From Convertor</COMMENTS>
   </TECHNICAL_SECTION>
   <LINKS_SECTION>
      <XML_SCHEMA_DEFINITION_LINK xlink:type="simple"
                                  xlink:href="http://ted.europa.eu"
                                  xlink:title="TED WEBSITE"/>
      <OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
   </LINKS_SECTION>
   <CODED_DATA_SECTION>
      <REF_OJS>
         <COLL_OJ>S</COLL_OJ>
         <NO_OJ>21</NO_OJ>
         <DATE_PUB>20180131</DATE_PUB>
      </REF_OJS>
      <NOTICE_DATA>
         <NO_DOC_OJS>2018/S 021-043485</NO_DOC_OJS>
         <URI_LIST>
            <URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:043485-2018:TEXT:EN:HTML</URI_DOC>
         </URI_LIST>
         <LG_ORIG>EN</LG_ORIG>
         <ISO_COUNTRY VALUE="UK"/>
         <IA_URL_GENERAL>http://www.procurement.wales.nhs.uk</IA_URL_GENERAL>
         <IA_URL_ETENDERING>https://etenderwales.bravosolution.co.uk/web/login.shtml</IA_URL_ETENDERING>
         <ORIGINAL_CPV CODE="33696500">Laboratory reagents</ORIGINAL_CPV>
         <n2016:PERFORMANCE_NUTS CODE="UKL">WALES</n2016:PERFORMANCE_NUTS>
         <n2016:CA_CE_NUTS CODE="UK">UNITED KINGDOM</n2016:CA_CE_NUTS>
         <VALUES>
            <VALUE TYPE="ESTIMATED_TOTAL" CURRENCY="GBP">1445870</VALUE>
         </VALUES>
      </NOTICE_DATA>
      <CODIF_DATA>
         <DS_DATE_DISPATCH>20180129</DS_DATE_DISPATCH>
         <DT_DATE_FOR_SUBMISSION>20180227 14:00</DT_DATE_FOR_SUBMISSION>
         <AA_AUTHORITY_TYPE CODE="6">Body governed by public law</AA_AUTHORITY_TYPE>
         <TD_DOCUMENT_TYPE CODE="3">Contract notice</TD_DOCUMENT_TYPE>
         <NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE>
         <PR_PROC CODE="1">Open procedure</PR_PROC>
         <RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION>
         <TY_TYPE_BID CODE="1">Submission for all lots</TY_TYPE_BID>
         <AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT>
         <MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES>
         <HEADING>01B02</HEADING>
         <INITIATOR>01</INITIATOR>
         <DIRECTIVE VALUE="2014/24/EU"/>
      </CODIF_DATA>
   </CODED_DATA_SECTION>
   <TRANSLATION_SECTION>
      <ML_TITLES>
         <ML_TI_DOC LG="BG">
            <TI_CY>Обединено кралство</TI_CY>
            <TI_TOWN>Кардиф</TI_TOWN>
            <TI_TEXT>
               <P>Лабораторни реактиви</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="CS">
            <TI_CY>Spojené království/Velká Británie</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratorní činidla</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DA">
            <TI_CY>Forenede Kongerige, Det</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratoriereagenser</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DE">
            <TI_CY>das Vereinigte Königreich</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laborreagenzien</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EL">
            <TI_CY>Ηνωμένο Βασίλειο</TI_CY>
            <TI_TOWN>Κάρντιφ</TI_TOWN>
            <TI_TEXT>
               <P>Αντιδραστήρια εργαστηρίων</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EN">
            <TI_CY>United Kingdom</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratory reagents</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ES">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Reactivos de laboratorio</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ET">
            <TI_CY>Suurbritannia / Ühendkuningriik</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratooriumireaktiivid</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FI">
            <TI_CY>Yhdistynyt kuningaskunta</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratorioreagenssit</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FR">
            <TI_CY>Royaume-Uni</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Réactifs de laboratoire</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="GA">
            <TI_CY>Ríocht Aontaithe, an</TI_CY>
            <TI_TOWN>Caerdydd</TI_TOWN>
            <TI_TEXT>
               <P>Laboratory reagents</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HR">
            <TI_CY>Ujedinjena Kraljevina</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratorijski reagensi</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HU">
            <TI_CY>Egyesült Királyság</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratóriumi reagensek</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="IT">
            <TI_CY>Regno Unito</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Reattivi per laboratorio</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LT">
            <TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY>
            <TI_TOWN>Kardifas</TI_TOWN>
            <TI_TEXT>
               <P>Laboratoriniai reagentai</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LV">
            <TI_CY>Apvienotā Karaliste</TI_CY>
            <TI_TOWN>Kārdifa</TI_TOWN>
            <TI_TEXT>
               <P>Laboratorijas reaģenti</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="MT">
            <TI_CY>Ir-Renju Unit</TI_CY>
            <TI_TOWN>Kardiff</TI_TOWN>
            <TI_TEXT>
               <P>Reaġenti tal-laboratorju</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="NL">
            <TI_CY>Verenigd Koninkrijk</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratoriumreagentia</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PL">
            <TI_CY>Zjednoczone Królestwo</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Odczynniki laboratoryjne</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PT">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Reagentes de laboratório</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="RO">
            <TI_CY>Regatul Unit</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Reactivi de laborator</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SK">
            <TI_CY>Spojené kráľovstvo</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratórne činidlá</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SL">
            <TI_CY>Združeno kraljestvo</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratorijski reagenti</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SV">
            <TI_CY>Förenade kungariket</TI_CY>
            <TI_TOWN>Cardiff</TI_TOWN>
            <TI_TEXT>
               <P>Laboratoriereagenser</P>
            </TI_TEXT>
         </ML_TI_DOC>
      </ML_TITLES>
      <ML_AA_NAMES>
         <AA_NAME LG="EN">NHS Wales Shared Services Partnership on behalf of Cardiff &amp; Vale University Health Board</AA_NAME>
      </ML_AA_NAMES>
   </TRANSLATION_SECTION>
   <FORM_SECTION>
      <NOTICE_UUID>91a313b4-661e-4673-9ed4-054e8d7ed1af</NOTICE_UUID>
      <F02_2014 CATEGORY="ORIGINAL" FORM="F02" LG="EN">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>NHS Wales Shared Services Partnership on behalf of Cardiff &amp; Vale University Health Board</OFFICIALNAME>
               <ADDRESS>8th Floor Brecknock House, University Hospital of Wales</ADDRESS>
               <TOWN>Cardiff</TOWN>
               <POSTAL_CODE>CF14 4XW</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <PHONE>+44 2920746577</PHONE>
               <E_MAIL>rhian.lye@wales.nhs.uk</E_MAIL>
               <n2016:NUTS CODE="UK"/>
               <URL_GENERAL>http://www.procurement.wales.nhs.uk</URL_GENERAL>
               <URL_BUYER>http://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <DOCUMENT_FULL/>
            <URL_DOCUMENT>https://etenderwales.bravosolution.co.uk/web/login.shtml</URL_DOCUMENT>
            <ADDRESS_FURTHER_INFO_IDEM/>
            <URL_PARTICIPATION>https://etenderwales.bravosolution.co.uk/web/login.shtml</URL_PARTICIPATION>
            <CA_TYPE VALUE="BODY_PUBLIC"/>
            <CA_ACTIVITY VALUE="HEALTH"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Next Generation Sequencing Panel (FFPE SAMPLES)</P>
            </TITLE>
            <REFERENCE_NUMBER>17/2390/EC</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="33696500"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SUPPLIES"/>
            <SHORT_DESCR>
               <P>Gene panel testing for those tumours where molecular results impact diagnosis, treatment or prognosis, is implemented on an all Wales basis.</P>
            </SHORT_DESCR>
            <VAL_ESTIMATED_TOTAL CURRENCY="GBP">1445870</VAL_ESTIMATED_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <CPV_ADDITIONAL>
                  <CPV_CODE CODE="33696500"/>
               </CPV_ADDITIONAL>
               <n2016:NUTS CODE="UKL"/>
               <SHORT_DESCR>
                  <P>The all Wales Genetic Laboratory (AWGL) has been delivering Precision Medicine molecular pathology services for cancer patients since 2008, and has been a UK leader in this field. Molecular services have been commissioned and delivered on a test-by-test basis as the associated therapy was approved for a given tumour type (e.g. KRAS, EGFR, BRAF, BRCA). This approach is now neither cost-effective, tissue-effective nor particularly rapid as multiple tests are performed for each tumour sample. It is therefore time to move to gene panel testing, as has been demonstrated in both the CR-UK Stratified Medicine Programme and the Novartis joint working agreement (both for lung cancer). The Novartis project currently funds gene panel testing for lung cancer patients in Cardiff until March 2017.</P>
                  <P>For many tumour types (or sub-types) there are still no associated targeted treatments. However, there is now a clinical need to molecularly characterise tumour samples for an increasing number of cancer types, to directly inform treatment or because new targeted treatments are anticipated imminently. For these sub-groups, there is additional utility in sign-posting patients towards molecularly stratified clinical trials. We have identified that patients with lung, colorectal, metastatic melanoma, head and neck, metastatic breast, ovarian, prostate, thyroid, and a small number of early onset breast cancer patients may benefit from this analysis.</P>
                  <P>We propose to develop and deliver universal gene panel testing on an all Wales basis for specific sub-groups of tumours where there is good clinical utility for current treatment decisions, and imminent treatment decisions. The delivery of gene panel tests for the above group of tumours will provide treating oncology teams with prognostic, predictive and sometimes diagnostic information to support their decision making. Therefore patients will benefit from molecularly directed treatment, where those treatments are available in Wales.</P>
                  <P>The project will tackle the requesting pathway from the multi-disciplinary team (MDT) and pathology (for tissue acquisition). A commercial universal gene panel of 25-30 genes will be established that will meet the molecular needs of all of the tumour types to be analysed, thus streamlining laboratory analysis and enabling automation. A bioinformatic pipeline will analyse those genes pertinent to the specific tumour type requested. We will introduce molecular tumour boards to support the interpretation of results within MDTs. The oncology teams will also consider the potential implications of IPFRs and increased referrals.</P>
                  <P>The AWGL is under pressure to deliver a gene panel service for cancer patients from requesters and patients, and frequently receives enquiries about this type of service. Molecular Pathology services worldwide are offering similar, or more extensive gene panel analysis. The proposed short-term project should determine if this service model is feasible, and delivers the anticipated patient benefits.</P>
               </SHORT_DESCR>
               <AC_PROCUREMENT_DOC/>
               <DURATION TYPE="MONTH">48</DURATION>
               <RENEWAL/>
               <RENEWAL_DESCR>
                  <P>2 years extension in 12 month tranches</P>
               </RENEWAL_DESCR>
               <NO_ACCEPTED_VARIANTS/>
               <NO_OPTIONS/>
               <NO_EU_PROGR_RELATED/>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <LEFTI>
            <ECONOMIC_CRITERIA_DOC/>
            <TECHNICAL_CRITERIA_DOC/>
         </LEFTI>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <DATE_RECEIPT_TENDERS>2018-02-27</DATE_RECEIPT_TENDERS>
            <TIME_RECEIPT_TENDERS>14:00</TIME_RECEIPT_TENDERS>
            <LANGUAGES>
               <LANGUAGE VALUE="EN"/>
            </LANGUAGES>
            <OPENING_CONDITION>
               <DATE_OPENING_TENDERS>2018-02-27</DATE_OPENING_TENDERS>
               <TIME_OPENING_TENDERS>14:30</TIME_OPENING_TENDERS>
            </OPENING_CONDITION>
         </PROCEDURE>
         <COMPLEMENTARY_INFO>
            <NO_RECURRENT_PROCUREMENT/>
            <INFO_ADD>
               <P>Please note additional information on this procurement:</P>
               <P>1. The Contracting Authority reserves the right to award the contract in whole, in part or annul the tendering process and not award any contract.</P>
               <P>2. Bidders should note that they will be required to enter into terms and conditions of contract as set out in the PQQ and ITT and that save for matters of clarification or consistency the Contracting Authority will not negotiate the terms.</P>
               <P>3. The Contracting Authority will not accept completed PQQ's and ITT's after the stated closing date.</P>
               <P>4. All documents to be priced (where applicable) in sterling and all payments made in sterling.</P>
               <P>5. All tender costs and liabilities incurred by bidders shall be the sole responsibility of the bidders.</P>
               <P>6. Prospective suppliers should note that NHS Shared Services Partnership - Procurement Services is acting on behalf of Cardiff and Vale University Local Health Board.</P>
               <P>Note: The authority is using eTenderwales to carry out this procurement process.</P>
               <P>Note: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at http://www.sell2wales.gov.wales/search/search_switch.aspx?ID=72210</P>
               <P>(WA Ref:76468).</P>
            </INFO_ADD>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>NHS Wales Shared Services Partnership on behalf of Cardiff &amp; Vale University Health Board</OFFICIALNAME>
               <ADDRESS>8th Floor, Brecknock House, University Hospital of Wales</ADDRESS>
               <TOWN>Cardiff</TOWN>
               <POSTAL_CODE>CF14 4XW</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <PHONE>+44 2920746246</PHONE>
               <E_MAIL>rhian.lye@wales.nhs.uk</E_MAIL>
               <URL>http://www.procurement.wales.nhs.uk</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Precise information on deadline(s) for review procedures:</P>
               <P>NHS Wales Shared Services Partnership on behalf of Cardiff and Vale University Local Health Board will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract.</P>
               <P>Unsuccessful tenderers and applicants are entitled to receive reasons for the decision, including the characteristics and relative advantages of the winning bid and the reasons why the tenderer/applicant was unsuccessful.</P>
               <P>Should additional information be required it should be requested of the addressee in section I.1.</P>
               <P>Aggrieved parties who have been harmed or are at risk of harm by breach of the procurement rules have the right to take action in the High Court (England and Wales). Any such action is subject to strict time limits in accordance with the Public Contracts (Amendments) Regulations 2015.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-29</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F02_2014>
   </FORM_SECTION>
</TED_EXPORT>
